.Attribute Medicine, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for incorporation of patients along with MASLD and also dimension of liver outcomes in cardio-- kidney-- metabolic trials, when data suggest mechanistically tenable perks as well as medical safety and security-- and outlines considerations for test layout and regulatory commendation.